Kyverna's Losses Widen Amid Soaring R&D Costs

TL;DR

**Kyverna is burning cash fast on R&D, and while new debt buys time, profitability remains a distant dream.**

AI Summary

Kyverna Therapeutics, Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $123.5 million, up from $89.988 million for the same period in 2024. This 37.2% increase in net loss was primarily driven by a substantial rise in research and development expenses, which climbed to $103.706 million in 2025 from $78.990 million in 2024, representing a 31.3% increase. The company's cash and cash equivalents decreased sharply from $96.621 million at December 31, 2024, to $34.164 million at September 30, 2025. Total assets also declined from $304.645 million to $187.156 million over the same period. Despite these losses, Kyverna secured $25.0 million in funding under a loan and security agreement with Oxford Finance LLC in October 2025, which management estimates will fund operations for at least the next 12 months. The company continues to focus on developing cell therapies for autoimmune diseases, with its lead product candidate, KYV-101, in late-stage clinical development.

Why It Matters

Kyverna's escalating net losses and significant cash burn raise concerns about its long-term financial viability, despite recent financing. Investors should scrutinize the efficacy and market potential of KYV-101, as continued heavy R&D investment without clear revenue pathways could lead to further dilution or funding challenges. For employees, the company's ability to secure future capital is critical for job security and continued research. Customers and the broader market will be impacted by the success or failure of KYV-101 in addressing autoimmune diseases, a competitive and high-stakes therapeutic area.

Risk Assessment

Risk Level: high — Kyverna reported an accumulated deficit of $387.0 million as of September 30, 2025, and net losses of $123.5 million for the nine months ended September 30, 2025. Cash and cash equivalents plummeted from $96.621 million to $34.164 million, indicating a rapid cash burn rate. The company explicitly states it expects to continue incurring operating losses and will need to raise additional capital, highlighting significant going concern risks.

Analyst Insight

Investors should exercise extreme caution and consider this a highly speculative investment. Monitor the progress of KYV-101's clinical trials closely and evaluate the terms and potential impact of the Oxford Finance LLC loan. Await further clarity on future funding strategies and clinical milestones before considering any significant position.

Financial Highlights

debt To Equity

Not Disclosed

revenue

Not Disclosed

operating Margin

Not Disclosed

total Assets

$187.156M

total Debt

Not Disclosed

net Income

-$123.5M

eps

Not Disclosed

gross Margin

Not Disclosed

cash Position

$34.164M

revenue Growth

N/A

Key Numbers

• $123.5M — Net Loss (for the nine months ended September 30, 2025, up from $89.988M in 2024)
• $103.706M — Research and Development Expenses (for the nine months ended September 30, 2025, a 31.3% increase from $78.990M in 2024)
• $34.164M — Cash and Cash Equivalents (as of September 30, 2025, down from $96.621M at December 31, 2024)
• $387.0M — Accumulated Deficit (as of September 30, 2025)
• $25.0M — New Funding (secured from Oxford Finance LLC in October 2025)
• 43,796,170 — Common Stock Shares Outstanding (as of October 31, 2025)

Key Players & Entities

• Kyverna Therapeutics, Inc. (company) — clinical-stage biopharmaceutical company
• Oxford Finance LLC (company) — lender providing $25.0 million in funding
• KYV-101 (product) — lead product candidate in late-stage clinical development
• SEC (regulator) — Securities and Exchange Commission
• FASB (regulator) — Financial Accounting Standards Board

FAQ

Risk Factors

• Significant Net Loss and Cash Burn [high — financial]: Kyverna reported a net loss of $123.5 million for the nine months ended September 30, 2025, a substantial increase from $89.988 million in the prior year period. This escalating loss is primarily driven by R&D expenses, which rose 31.3% to $103.706 million. The company's cash and cash equivalents plummeted from $96.621 million at the end of 2024 to $34.164 million by September 30, 2025, indicating a rapid depletion of resources.
• Dependence on Future Funding [high — financial]: The sharp decline in cash reserves to $34.164 million raises concerns about the company's ability to sustain operations without additional capital. While management secured $25.0 million in funding in October 2025, which they estimate will cover operations for at least 12 months, this is a short-term solution. Further funding rounds will be critical to support ongoing clinical development and commercialization efforts.
• Clinical Trial Success and Regulatory Approval [high — regulatory]: Kyverna's lead product candidate, KYV-101, is in late-stage clinical development. The success of these trials and subsequent approval from regulatory bodies like the FDA are paramount. Any delays, adverse findings, or failure to gain approval would severely impact the company's prospects and financial viability.
• Execution of Clinical Development and Manufacturing [medium — operational]: The company's ability to successfully execute complex clinical trials, manage manufacturing processes for cell therapies, and scale up production if approved are significant operational risks. Any missteps in these areas could lead to costly delays and reputational damage.
• Competition in Autoimmune Disease Therapies [medium — market]: The market for autoimmune disease treatments is competitive, with established players and emerging biotech companies developing novel therapies. Kyverna faces the risk of competitors achieving market success with similar or superior treatments, potentially limiting KYV-101's market penetration and pricing power.
• Accumulated Deficit [medium — financial]: As of September 30, 2025, Kyverna has an accumulated deficit of $387.0 million. This reflects the significant historical losses incurred in pursuit of its product development goals. Continued losses are expected, and the company will need to achieve profitability through successful commercialization to overcome this deficit.

Industry Context

Kyverna Therapeutics operates in the highly competitive biotechnology sector, specifically focusing on cell therapies for autoimmune diseases. This field is characterized by rapid innovation, significant R&D investment, and lengthy, expensive clinical trial processes. Key trends include the development of targeted therapies and the increasing complexity of manufacturing advanced biologics.

Regulatory Implications

The development of cell therapies is subject to stringent regulatory oversight from agencies like the FDA. Successful navigation of clinical trial phases, adherence to manufacturing standards (cGMP), and obtaining marketing approval are critical hurdles. Any delays or setbacks in the regulatory process pose a significant risk to commercialization timelines and financial projections.

What Investors Should Do

1. Monitor upcoming clinical trial data releases for KYV-101 closely, as trial success is paramount to future valuation.
2. Assess the company's ability to secure additional funding beyond the current 12-month runway, given the high cash burn rate.
3. Evaluate the competitive landscape and potential market penetration for KYV-101 against existing and emerging treatments for autoimmune diseases.
4. Scrutinize management's execution capabilities regarding clinical development and potential future manufacturing scale-up.

Key Dates

• 2025-09-30: End of third quarter reporting period — Key period for assessing financial health, showing a significant increase in net loss and a sharp decrease in cash.
• 2025-10-31: Common stock shares outstanding reported — Provides insight into the company's equity structure as of a recent date.
• 2025-10: Secured $25.0 million loan facility — Provides crucial short-term funding to extend operational runway, mitigating immediate liquidity concerns.

Glossary

Accumulated Deficit

The total net losses a company has incurred since its inception, minus any net gains. It represents a negative balance in retained earnings. (Indicates the company has historically spent more than it has earned, a common trait for development-stage biotech firms, highlighting the need for future profitability.)

Cash and Cash Equivalents

Includes cash on hand, bank deposits, and short-term, highly liquid investments with original maturities of three months or less. (A critical measure of a company's immediate liquidity and ability to meet short-term obligations. The sharp decrease highlights significant cash burn.)

Net Loss

The total expenses incurred by a company exceed its total revenues over a specific period. (Shows the company's profitability (or lack thereof) during the reporting period. The increase in net loss is a key concern.)

Research and Development Expenses (R&D)

Costs incurred by a company in the process of developing new products or services, or improving existing ones. For biotech, this includes clinical trials, lab work, and personnel. (A major expense driver for biotech companies. The significant increase in R&D spending reflects ongoing investment in pipeline development, particularly for KYV-101.)

Year-Over-Year Comparison

Compared to the prior year period, Kyverna Therapeutics has experienced a significant increase in its net loss, rising by 37.2% to $123.5 million for the nine months ended September 30, 2025. This deterioration is largely attributable to a 31.3% surge in R&D expenses. Concurrently, the company's liquidity position has weakened considerably, with cash and cash equivalents dropping from $96.621 million at year-end 2024 to $34.164 million by the end of the third quarter of 2025, indicating an accelerated burn rate.

Key Financial Figures

• $0.00001 — ch registered Common Stock, par value $0.00001 per share KYTX The Nasdaq Stock Mar

Filing Documents

• kytx-20250930.htm (10-Q) — 3000KB
• kytx-ex31_1.htm (EX-31.1) — 18KB
• kytx-ex31_2.htm (EX-31.2) — 18KB
• kytx-ex32_1.htm (EX-32.1) — 12KB
• kytx-ex32_2.htm (EX-32.2) — 12KB
• img189408674_0.jpg (GRAPHIC) — 732KB
• 0001193125-25-277584.txt ( ) — 11532KB
• kytx-20250930.xsd (EX-101.SCH) — 1164KB
• kytx-20250930_htm.xml (XML) — 1643KB

Financial Statements (Unaudited)

Financial Statements (Unaudited) 1 Condensed Balance Sheets 1 Condensed Statements of Operations and Comprehensive Loss 2 Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) 3 Condensed Statements of Cash Flows 4 Notes to Unaudited Condensed Financial Statements 5 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 19 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 31 Item 4.

Controls and Procedures

Controls and Procedures 31 PART II. OTHER INFORMATION 34 Item 1.

Legal Proceedings

Legal Proceedings 34 Item 1A.

Risk Factors

Risk Factors 34 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 99 Item 3. Defaults Upon Senior Securities 99 Item 4. Mine Safety Disclosures 99 Item 5. Other Information 100 Item 6. Exhibits 101

Signatures

Signatures 102 i

—FIN ANCIAL INFORMATION

PART I—FIN ANCIAL INFORMATION Ite m 1. Financial Statements (unaudited) Kyverna Therapeutics, Inc. Con densed Balance Sheets (in thousands, except share and per share data) (unaudited) September 30, December 31, 2025 2024 Assets Current assets Cash and cash equivalents $ 34,164 $ 96,621 Available-for-sale marketable securities 136,974 189,358 Prepaid expenses and other current assets 3,787 4,622 Total current assets 174,925 290,601 Restricted cash 551 552 Property and equipment, net 1,793 3,347 Operating lease right-of-use assets 4,317 6,468 Finance lease right-of-use assets 212 841 Other non-current assets 5,358 2,836 Total assets $ 187,156 $ 304,645 Liabilities and stockholders' equity Current liabilities Accounts payable $ 3,016 $ 4,624 Accrued compensation 6,960 4,883 Accrued license expense – related party 6,250 6,250 Other accrued expenses and current liabilities 13,960 14,059 Operating lease liabilities, short-term portion 3,495 3,161 Finance lease liabilities, short-term portion 190 779 Total current liabilities 33,871 33,756 Operating lease liabilities, net of short-term portion 1,331 4,160 Finance lease liabilities, net of short-term portion 8 142 Total liabilities 35,210 38,058 Commitments and contingencies (Note 7) Stockholders' equity Preferred stock, 10,000,000 shares authorized, $ 0.00001 par value, no shares issued and outstanding at September 30, 2025 and December 31, 2024 — — Common stock, $ 0.00001 par value; 490,000,000 shares authorized as of September 30, 2025 and December 31, 2024, respectively; 43,794,087 and 43,214,918 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively. — — Additional paid-in capital 538,940 530,002 Accumulated other comprehensive income 29 105 Accumulated deficit ( 387,023 ) ( 263,520 ) Tot

View Full Filing

View this 10-Q filing on SEC EDGAR